Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Seven RNAi-Related Patent Applications: Sep 20, 2007

Premium
Title: Nucleic Acid Molecules as Herpanase Potent Inhibitors, Compounds and Methods of Use Thereof
 
Number: 20070212330
 
Filed: June 1, 2005 PCT Filed: June 1, 2005
 
Lead Inventor: Israel Vlodavsky, Hadassah-Hebrew University of Medical Center
 
The invention, the patent application’s abstract states, relates to ”ribonucleic acid molecules, specifically ribozymes and siRNAs, whose sequence is at least partially complementary to heparanase mRNA. Said molecules may thus be used for the specific inhibition of heparanase, and as therapeutics for pathologic conditions associated with heparanase expression, for example tumor formation, progression and metastasis, tumor-associated angiogenesis, inflammatory disorders, kidney disorders, and autoimmune disorders. Vectors, cells, and compositions comprising said ribonucleic acid molecules are also disclosed” in the application, the abstract adds
 

 
Title: Intron Double-Stranded RNA Constructs and Uses Thereof
 
Number: 20070212780
 
Filed: May 31, 2007
 
Inventor: JoAnne Fillatti, Calgene
 
The invention, according to the patent application’s abstract, “is in the field of plant genetics and provides agents capable of gene-specific silencing. The … invention specifically provides double-stranded RNA agents, methods for utilizing such agents, and plants containing such agents.”
 

 
Title: Method of Selecting Targets for Gene Silencing by RNA Interference
 
Number: 20070213284
 
Filed: Nov. 24, 2004
 
Lead Inventor: Muhammad Sohail, University of Oxford
 
“The invention relates to the selection of target regions of RNA transcripts for specific down-regulation of gene expression by RNA interference,” the patent application’s abstract states. “Target regions of the transcript are identified on the basis of hybridization to scanning arrays of antisense oligonucleotides and siRNA reagents comprising double-stranded RNAs corresponding to the target regions are then synthesized.”
 

 
Title: Chemically Modified Oligonucleotides for Use in Modulating microRNA and Uses Thereof
 
Number: 20070213292
 
Filed: Jan. 24, 2007
 
Lead Inventor: Markus Stoffel Rockefeller University (Alnylam Pharmaceuticals)
 
“This invention relates generally to chemically modified oligonucleotides useful for modulating expression of microRNAs and pre-microRNAs,” the patent application’s abstract states. “More particularly, the invention relates to single-stranded, chemically modified oligonucleotides for inhibiting microRNA and pre-microRNA expression and to methods of making and using the modified oligonucleotides. Also included in the invention are compositions and methods for silencing microRNAs in the central nervous system.”
 

 
Title: RNAi Therapeutic for Respiratory Virus Infection
 
Number: 20070213293
 
Filed: March 16, 2007
 
Lead Inventor: James McSwiggen, Nastech Pharmaceutical
 
The patent application, its abstract states, claims “double-stranded siRNA molecules for combating a respiratory virus, wherein the strands of an siRNA molecule may be from about 15 to about 60 nucleotides, and uses thereof. One strand of an siRNA molecule can be a nucleic acid sequence identical to a conserved site, or a variant thereof, within the nucleic acid sequence of the respiratory virus.”
 

 
Title: siRNA Targeting Calcium/Calmodulin-Dependent Protein Kinase IV
 
Number: 20070213520
 
Filed: April 6, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CAMK4.”
 

 
Title: siRNA Targeting Cell Division Cycle 25
 
Number: 20070213521
 
Filed: April 9, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CDC25C.”